ClinSpec Diagnostics reaches funding target of £3.5m
5th March 2021
Glasgow-based ClinSpec Diagnostics has secured an additional £1.1m investment, reaching its round two funding target of £3.5m.
ClinSpec, a spin-out company from the University of Strathclyde’s Department of Pure and Applied Chemistry, is aiming to develop liquid biopsies for the early detection of cancer.
The new £1.1m investment from the latest funding round comes from a range of investors, including Norcliffe Capital Limited, the University of Strathclyde, Eos Advisory and the founders.
The first £2.4m was secured in 2020, with that funding round led by Mercia’s EIS Funds with Scottish Enterprise, SIS Ventures, Eos Advisory and the University of Strathclyde.
Swift Biosciences and SPT Labtech Announce Accelerated Research Collaboration
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Swift Biosciences and SPT Labtech Announce Accelerated Research Collaboration
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Dublin, Feb. 25, 2021 (GLOBE NEWSWIRE) The "Molecular Diagnostics for Cancer - Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025" report has been added to ResearchAndMarkets.com's offering. A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Working against this dynamic market are the forces of the COVID Driven Recession. The publis
(1)
Circulating cell-free mRNA in blood reflective of NAFLD/NASH liver pathology
PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the company s Next-Generation cell-free mRNA Liquid Biopsy Technology Platform. The study titled Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization was published in the
American Journal of Physiology -
Gastrointestinal and Liver Physiology, a journal of the American Physiological Society. The first author is Naga Chalasani, M.D., Professor of Gastroenterology and Hepatology and Interim Chair in the Department of Medicine at Indiana University in the USA. Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and